Methamphetamine fails to alter the noradrenergic integrity of the heart: A comparison with the parkinsonism-inducing neurotoxin MPTP

Annals of the New York Academy of Sciences

Volumn 1139, Issue , 2008, Pages 337-344

  Ruffoli, Riccardo ^a   Soldani, Paola ^a   Pasquali, Livia ^a   Ruggieri, Stefano ^b   Paparelli, Antonio ^a   Fornai, Francesco ^a,b  

^a UNIVERSITY OF PISA   (Italy)

^b Laboratory of Neurobiology of Movement Disorders   (Italy)

Author keywords

Cardiac noradrenergic innervation; Methamphetamine; MPTP; Parkinson's disease; Parkinsonian heart

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; METHAMPHETAMINE;

ADOLESCENT; ANIMAL EXPERIMENT; CARDIOMYOPATHY; CARDIOVASCULAR EFFECT; CONFERENCE PAPER; HEART MUSCLE FIBROSIS; MALE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENERGIC SYSTEM; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM;

PARKINSONIA;

EID: 53549087549     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1432.017     Document Type: Conference Paper

References (64)

1. Battaglia, G., F. Fornai, C.L. Busceti, et al. 2002. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against methamphetamine neurotoxicity. J. Neurosci. 22 : 2135 2141.
2. Davis, G.C., A.C. Williams, S.P. Markey, et al. 1979. Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1 : 249 254.
3. Langston, J.W., P. Ballard, J.W. Tetrud, et al. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 : 979 980.
4. Ehringer, H. & O. Hornykiewicz. 1960. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin. Wochenschr. 38 : 1236 1239.
5. Braak, H. & E. Braak. 2000. Pathoanatomy of Parkinson's disease. J. Neurol. 247 (Suppl. 2 II3 II10.
6. Del Tredici, K., U. Rub, R.A. De Vos, et al. 2002. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61 : 413 426.
7. Braak, H., K. Del Tredici, U. Rub, et al. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24 : 197 211.
8. rd., et al. 1992. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32 : 667 676.
9. Zarow, C., S.A Lyness, J.A. Mortimer, et al. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60 : 337 341.
10. Tong, J., O. Hornykiewicz & S.J. Kish. 2006. Inverse relationship between brain noradrenaline level and dopamine loss in Parkinson disease, a possible neuroprotective role for noradrenaline. Arch. Neurol. 63 : 1724 1728.
11. Mavridis, M., A.D. Degryse, A.J. Lategan, et al. 1991. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience 41 : 507 523.
12. Marien, M., M. Briley & F. Colpaert. 1993. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 4 : 487 489.
13. Bing, G., Y. Zhang, Y. Watanabe, et al. 1994. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668 : 261 265.
14. Fornai, F., L. Bassi, M.T. Torracca, et al. 1995. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283 : 99 102.
15. Fornai, F., L. Bassi, M.T. Torracca, et al. 1996. Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration 5 : 241 249.
16. Fornai, F., M.G. Alessandrì, M.T. Torracca, et al. 1997. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther. 283 : 100 107.
17. Fornai, F., F.S. Giorgi, M.G. Alessandrì, et al. 1999. Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem. 72 : 777 784.
18. Soldani, P. & F. Fornai. 1999. The functional anatomy of noradrenergic neurons in Parkinson's disease. Funct. Neurol. 14 : 97 109.
19. Gesi, M., P. Soldani, F.S. Giorgi, et al. 2000. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 24 : 655 668.
20. Marien, M.R., F.C. Colpaert & A.C. Rosenquist. 2004. Noradrenergic mechanisms in neurodegenerative diseases, a theory. Brain Res. Rev. 45 : 38 48.
21. Goldstein, D.S., C. Holmes, R.O. Cannon, et al. 1997. Sympathetic cardioneuropathy in dysautonomias. N. Engl. J. Med. 336 : 696 702.
22. Goldstein, D.S., C. Holmes, S.T. Li, et al. 2000. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133 : 338 347.
23. Senard, J.M., C. Brefel-Courbon, O. Rascol, et al. 2001. Orthostatic hypotension in patients with Parkinson's disease, pathophysiology and management. Drugs Aging 18 : 495 505.
24. Goldstein, D.S. 2003. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2 : 669 676.
25. Amino, T., S. Orimo, Y. Itoh, et al. 2005. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 15 : 29 34.
26. Oka, H., S. Mochio, M. Yoshioka, et al. 2006. Cardiovascular dysautonomia in Parkinson's disease and multiple system atrophy. Acta Neurol. Scand. 113 : 221 227.
27. Oka, H., S. Mochio, K. Onouchi, et al. 2006. Cardiovascular dysautonomia in de novo Parkinson's disease. J. Neurol. Sci. 241 : 59 62.
28. Oka, H., M. Morita, K. Onouchi, et al. 2007. Cardiovascular autonomic dysfunction in dementia with Lewy bodies and Parkinson's disease. J. Neurol. Sci. 254 : 72 77.
29. Goldstein, D.S., Y. Sharabi, B.I. Karp, et al. 2007. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin. Auton. Res. 17 : 118 121.
30. Zolkowska, D., R.B. Rothman & M.H. Baumann. 2006. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J. Pharmacol. Exp. Ther. 318 : 604 610.
31. Newton, T.F., R. De La Garza II., A.D. Kalechstein, et al. 2005. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol. Biochem. Behav. 82 : 90 97.
32. Yeo, K.K., M. Wijetunga, H. Ito, et al. 2007. The association of methamphetamine use and cardiomyopathy in young patients. Am. J. Med. 120 : 165 171.
33. Goldstein, D.S., C. Holmes, S.T. Li, et al. 2000. Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133 : 338 347.
34. Kopin, I.J., B. Rundqvist, P. Friberg, et al. 1998. Different relationships of spillover to release of norepinephrine in human heart, kidneys, and forearm. Am. J. Physiol. 275 : R165 R173.
35. Eisenhofer, G., P. Friberg, B. Rundqvist, et al. 1996. Cardiac sympathetic nerve function in congestive heart failure. Circulation 93 : 1667 1676.
36. 123I]iodobenzylguanidine in Parkinson's disease with autonomic failure. Acta Neurol. Scand. 97 : 307 314.
37. Meredith, I.T., M.D. Esler, H.S. Cox, et al. 1991. Biochemical evidence of sympathetic denervation of the heart in pure autonomic failure. Clin. Auton. Res. 1 : 187 194.
38. Orimo, S., E. Ozawa, T. Oka, et al. 2001. Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57 : 1140 1141.
39. Fornai, F., M. Saviozzi, S. Piaggi, et al. 1999. Localization of a glutathione-dependent dehydroascorbate reductase within the central nervous system of the rat. Neuroscience 94 : 937 948.
40. Robertson, D., A.S. Hollister, I. Biaggioni, et al. 1993. The diagnosis and treatment of baroreflex failure. N. Engl. J. Med. 329 : 1449 1455.
41. Fornai F., R. Ruffoli, P. Soldani, et al. 2007. The "parkinsonian heart": from novel vistas to advanced therapeutic approaches in Parkinson's disease. Curr. Med. Chem. 14 : 2421 2428.
42. Neri, M., D. Cerretani, A.I. Fiaschi, et al. 2007. Correlation between cardiac oxidative stress and myocardial pathology due to acute and chronic norepinephrine administration in rats. J. Cell. Mol. Med. 11 : 156 170.
43. Kondo, M., Y. Ueda, M. Makino, et al. 2000. Worsened orthostatic hypotension due to levodopa administration in a case of Parkinson's disease. Nippon Ronen. Igakkai. Zasshi. 37 : 255 258.
44. Hoehn, M.M. 1975. Levodopa-induced postural hypotension: treatment with ludrocortisone. Arch. Neurol. 32 : 50 51.
45. Kujawa, K., S. Leurgans, R. Raman, et al. 2000. Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease. Arch. Neurol. 57 : 1461 1463.
46. Emilien, G., J.M. Maloteaux, M. Geurts, et al. 1999. Dopamine receptors: physiological understanding to therapeutic intervention potential. Pharmacol. Ther. 84 : 133 156.
47. Zanettini, R., A. Antonini, G. Gatto, et al. 2007. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356 : 39 46.
48. Schade, R., F. Andersohn, S. Suissa, et al. 2007. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356 : 29 38.
49. Millan, M.J., L. Maiofiss, D. Cussac, et al. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303 : 791 804.
50. Kvernmo, T., S. Hartter & E. Burger. 2006. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin. Ther. 28 : 1065 1078.
51. Antonini, A. & W. Poewe. 2007. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. 6 : 826 829.
52. 2B receptor agonism in cardiac valvular fibrosis. Clin. Neuropharmacol. 29 : 80 86.
53. Devereux, R.B. 1998. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339 : 765 766.
54. Rothman, R.B., M.H. Baumann, J.E. Savage, et al. 2000. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102 : 2836 2841.
55. Setola, V. & B.L. Roth. 2005. Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen'. Exp. Opin. Drug Metab. Toxicol. 1 : 377 387.
56. Roth, B.L. 2007. Drugs and valvular heart disease. N. Engl. J. Med. 356 : 6 9.
57. Connolly, H.M., J.L. Crary, M.D. McGoon, et al. 1997. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337 : 581 588.
58. Setola, V., S.J. Hufeisen, K.J. Grande-Allen, et al. 2003. 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferate actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63 : 1223 1229.
59. 1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J. Mol. Cell. Cardiol. 40 : 540 542.
60. Perlini, S., G. Palladini, I. Ferrero, et al. 2005. Sympathectomy or doxazosin, but not propranolol, blunts myocardial interstitial fibrosis in pressure-overload hypertrophy. Hypertension 46 : 1213 1218.
61. Fowler, J.S., C. Kroll, R. Ferrieri, et al. 2007. PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine. J. Nucl. Med. 48 : 1724 1732.
62. Pavese, N., O. Rimoldi, A. Gerhard, et al. 2004. Cardiovascular effects of methamphetamine in Parkinson's disease patients. Mov. Disord. 19 : 298 303.
63. Ago, M., K. Ago, K. Hara, et al. 2006. Toxicological and histopathological analysis of a patient who died nine days after a single intravenous dose of methamphetamine: a case report. Leg. Med. (Tokyo) 8 : 235 239.
64. Maeno, Y., M. Iwasa, H. Inoue, et al. 2000. Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes. Int. J. Legal. Med. 113 : 201 207.